EGFR and neoplasm: Altogether, data from colorectal cancer and NSCLC suggest that p65BTK is an emerging actionable target in tumour cells resistant to chemotherapy and scarcely responsive to target therapy because of lack of EGFR mutation or presence of activated KRAS [26, 27].